| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5703079 | SCHERING | Tetrahydrofuran antifungals |
Aug, 2014
(9 years ago) | |
| US6958337 | SCHERING | Crystalline antifungal polymorph |
Oct, 2018
(5 years ago) | |
| US5661151 | SCHERING | Tetrahydrofuran antifungals |
Jul, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263600 | SCHERING | Antifungal composition with enhanced bioavailability |
Apr, 2022
(2 years ago) | |
Noxafil is owned by Schering.
Noxafil contains Posaconazole.
Noxafil has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Noxafil are:
- US8263600
- US5703079
- US6958337
- US5661151
Noxafil was authorised for market use on 15 September, 2006.
Noxafil is available in suspension;oral dosage forms.
Noxafil can be used as prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis.
Drug patent challenges can be filed against Noxafil from 15 September, 2010.
The generics of Noxafil are possible to be released after 01 April, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
Drugs and Companies using POSACONAZOLE ingredient
NCE-1 date: 15 September, 2010
Market Authorisation Date: 15 September, 2006
Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis
Dosage: SUSPENSION;ORAL
NOXAFIL family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5703079 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Aug, 2014
(9 years ago) | |
| US5661151 | MERCK SHARP DOHME | Tetrahydrofuran antifungals |
Jul, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(7 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(7 years from now) | |
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
Noxafil is owned by Merck Sharp Dohme.
Noxafil contains Posaconazole.
Noxafil has a total of 8 drug patents out of which 2 drug patents have expired.
Expired drug patents of Noxafil are:
- US5703079
- US5661151
Noxafil was authorised for market use on 13 March, 2014.
Noxafil is available in solution;intravenous, tablet, delayed release;oral dosage forms.
Noxafil can be used as prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised, prophylaxis of invasive aspergillus and candida infections.
The generics of Noxafil are possible to be released after 27 February, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 31, 2024 |
| Orphan Drug Exclusivity(ODE-355) | Jun 17, 2028 |
| New Indication(I-881) | Jun 17, 2024 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Treatment: Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida...
Dosage: SOLUTION;INTRAVENOUS; TABLET, DELAYED RELEASE;ORAL
NOXAFIL family patents